From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan

TEL AVIV, Israel, July 1, 2019

Summary of Highlights (read the full report here)

Entera Bio's platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability. By transforming injectable drugs to oral drugs, the treatment becomes more 'user friendly' which may lead to higher patient and physician acceptance and enables personalized care.

On December 11^th 2018, Entera Bio announced a research collaboration and license agreement with Amgen in the area of inflammatory disease and other serious illnesses totaling up to $270 million in milestone payments as well as a mid-single digit royalty on commercial sales.

The Company's main focus is applying its technology to develop an oral formulation of human parathyroid hormone (1-34), or PTH, which has been approved in the U.S. and the EU in injectable form for over a decade. Entera Bio received positive feedback from the FDA regarding its 505(b)(2) regulatory pathway which saves years and money in development. Entera Bio's lead oral PTH product candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism.

We view Entera Bio as a great investment opportunity: the Amgen agreement and the regulatory path transformation will positively and significantly affect time-to-market and investor exposure to the Company's platform of large molecule delivery. 

Read the full report here